|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stein JP, Lieskovsky G, Cote R, Groshen S,
Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M,
et al: Radical cystectomy in the treatment of invasive bladder
cancer: Long-term results in 1,054 patients. J Clin Oncol.
19:666–675. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lenis AT, Lec PM, Chamie K and Mshs MD:
Bladder cancer: A review. JAMA. 324:1980–1991. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sarfaty M and Rosenberg JE: Antibody-drug
conjugates in urothelial carcinomas. Curr Oncol Rep.
22(13)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kamoun A, de Reyniès A, Allory Y, Sjödahl
G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H,
Choi W, et al: A consensus molecular classification of
muscle-invasive bladder cancer. Eur Urol. 77:420–433.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yarden Y: Biology of HER2 and its
importance in breast cancer. Oncology. 61 (Suppl 2):1–13.
2001.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hindy JR, Souaid T, Kourie HR and Kattan
J: Targeted therapies in urothelial bladder cancer: A disappointing
past preceding a bright future? Future Oncol. 15:1505–1524.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun
Y and Xu C: Prognostic role of HER2 expression in bladder cancer: A
systematic review and meta-analysis. Int Urol Nephrol. 47:87–94.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen PC, Yu HJ, Chang YH and Pan CC: Her2
amplification distinguishes a subset of non-muscle-invasive bladder
cancers with a high risk of progression. J Clin Pathol. 66:113–119.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kim D, Kim JM, Kim JS, Kim S and Kim KH:
Differential expression and clinicopathological significance of
HER2, indoleamine 2,3-dioxygenase and PD-L1 in urothelial carcinoma
of the bladder. J Clin Med. 9(1265)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Krüger S, Weitsch G, Büttner H,
Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC and Böhle
A: HER2 overexpression in muscle-invasive urothelial carcinoma of
the bladder: Prognostic implications. Int J Cancer. 102:514–518.
2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Abdelrahman AE, Rashed HE, Elkady E,
Elsebai EA, El-Azony A and Matar I: Fatty acid synthase, Her2/neu,
and E2F1 as prognostic markers of progression in non-muscle
invasive bladder cancer. Ann Diagn Pathol. 39:42–52.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kolla SB, Seth A, Singh MK, Gupta NP,
Hemal AK, Dogra PN and Kumar R: Prognostic significance of Her2/neu
overexpression in patients with muscle invasive urinary bladder
cancer treated with radical cystectomy. Int Urol Nephrol.
40:321–327. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bolenz C, Shariat SF, Karakiewicz PI,
Ashfaq R, Ho R, Sagalowsky AI and Lotan Y: Human epidermal growth
factor receptor 2 expression status provides independent prognostic
information in patients with urothelial carcinoma of the urinary
bladder. BJU Int. 106:1216–1222. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jimenez RE, Hussain M, Bianco FJ Jr,
Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr and
Grignon DJ: Her-2/neu overexpression in muscle-invasive urothelial
carcinoma of the bladder: Prognostic significance and comparative
analysis in primary and metastatic tumors. Clin Cancer Res.
7:2440–2447. 2001.PubMed/NCBI
|
|
19
|
Kassouf W, Black PC, Tuziak T, Bondaruk J,
Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, et al:
Distinctive expression pattern of ErbB family receptors signifies
an aggressive variant of bladder cancer. J Urol. 179:353–358.
2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Soria F, Moschini M, Haitel A, Wirth GJ,
Gust KM, Briganti A, Rouprêt M, Klatte T, Hassler MR, Karakiewicz
PI and Shariat SF: The effect of HER2 status on oncological
outcomes of patients with invasive bladder cancer. Urol Oncol.
34:533.e1–533.e10. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gandour-Edwards R, Lara PN Jr, Folkins AK,
LaSalle JM, Beckett L, Li Y, Meyers FJ and DeVere-White R: Does
HER2/neu expression provide prognostic information in patients with
advanced urothelial carcinoma? Cancer. 95:1009–1015.
2002.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: AJCC cancer staging manual (ed
6). New York, NY, Springer-Verlag, 2002.
|
|
23
|
Mostofi FK, Sobin LH and Torloni H: World
Health Organization (WHO): Histological typing of urinary bladder
tumours / F. K. Mostofi, in collaboration with L. H. Sobin, H.
Torloni and pathologists in fourteen countries. WHO, Geneva,
1973.
|
|
24
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical oncology/college of
American pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sanguedolce F, Russo D, Mancini V,
Selvaggio O, Calò B, Carrieri G and Cormio L: Human epidermal
growth factor receptor 2 in non-muscle invasive bladder cancer:
Issues in assessment methods and its role as prognostic/predictive
marker and putative therapeutic target: A comprehensive review.
Urol Int. 102:249–261. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Diéras V, Miles D, Verma S, Pegram M,
Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, et al:
Trastuzumab emtansine versus capecitabine plus lapatinib in
patients with previously treated HER2-positive advanced breast
cancer (EMILIA): A descriptive analysis of final overall survival
results from a randomised, open-label, phase 3 trial. Lancet Oncol.
18:732–742. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Krop IE, Kim SB, Martin AG, LoRusso PM,
Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M and Wildiers
H: Trastuzumab emtansine versus treatment of physician's choice in
patients with previously treated HER2-positive metastatic breast
cancer (TH3RESA): Final overall survival results from a randomised
open-label phase 3 trial. Lancet Oncol. 18:743–754. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Modi S, Saura C, Yamashita T, Park YH, Kim
SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al:
Trastuzumab deruxtecan in previously treated HER2-positive breast
cancer. N Engl J Med. 382:610–621. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo
H, Shi B, Liu J, He Z, Yu G, et al: Open-label, multicenter, phase
II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in
patients with locally advanced or metastatic urothelial carcinoma.
Clin Cancer Res. 27:43–51. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gan K, Gao Y, Liu K, Xu B and Qin W: The
clinical significance and prognostic value of HER2 expression in
bladder cancer: A meta-analysis and a bioinformatic analysis. Front
Oncol. 11(653491)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gutierrez C and Schiff R: HER2: biology,
detection, and clinical implications. Arch Pathol Lab Med.
135:55–62. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ménard S, Pupa SM, Campiglio M and
Tagliabue E: Biologic and therapeutic role of HER2 in cancer.
Oncogene. 22:6570–6578. 2003.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Fleischmann A, Rotzer D, Seiler R, Studer
UE and Thalmann GN: Her2 amplification is significantly more
frequent in lymph node metastases from urothelial bladder cancer
than in the primary tumours. Eur Urol. 60:350–357. 2011.PubMed/NCBI View Article : Google Scholar
|
